Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease Clinical Trial

Official title:

A Single Blind, Placebo-controlled, Randomised Study in Mild to Moderate Alzheimer's Disease Patients to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK239512, a Selective Histamine H3 Receptor Antagonist

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00675090
• Other study ID #: H3B109689
• Status: Completed
• Phase: Phase 1
• First received: April 24, 2008
• Last updated: July 5, 2017
• Start date: February 21, 2008
• Est. completion date: June 16, 2009

Study information

• Verified date: July 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a safety and tolerability study to investigate the effect of GSK239512 on mild to moderate Alzheimers disease patients. The dose of GSK239512 will be titrated to reach the most well tolerated dose in the patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: June 16, 2009
• Est. primary completion date: June 16, 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Male or female subjects with a clinical diagnosis of probable Alzheimer's disease

• The subject has an MMSE score at screening of 12 to 26 for Part A and 16-26 for Part B.

• Age = 50 and above.

• If female, the subject must be post-menopausal (i.e. 12 months without menstrual period) or surgically sterile.

• Male subjects must be willing to abstain from sexual intercourse with pregnant or lactating women; or be willing to use a condom/spermicide in addition to having their female partner use another form of contraception if the woman could become pregnant, from the time of the first dose of GSK239512 until 84 days following completion of the study.

• The subject has the ability to comply with the study procedures.

• The subject has a permanent caregiver and is willing to attend all study visits for Parts A and B.

• The subject has provided full written informed consent prior to the performance of any protocol specific procedure, or if unable to provide informed consent due to cognitive status, full written informed consent on behalf of the subject has been provided by a legally acceptable representative.

• The caregiver has provided his / her written consent prior to the performance of any protocol specific procedure.

Exclusion Criteria:

• In the opinion of the investigator, following review of CT/MRI scans in the past 12 months and completion of neurological review there could be other probable causes of dementia

• History of significant psychiatric illness such as schizophrenia or bipolar affective disorder that in the opinion of the Investigator would interfere with participation in the study, or current depression (a score of =8 on the Cornell Scale for Depression in Dementia), or subjects with other psychiatric features in their AD which would in the opinion of the investigator, would increase risk to safety.

• History of significant sleep disturbance, for example, when it is associated with nocturnal wandering, nocturnal confusion / disorientation / agitation, which in the opinion of the investigator, may increase safety risk.

• History or presence of known or suspected seizures, unexplained significant loss of consciousness within last 6 months. Subjects who had febrile seizures in childhood may be included if these ceased by age 10 and they have had no other type of seizure in their medical history and have not been on anti-epileptic medications.

• History or presence of significant cardiovascular, gastro-intestinal, hepatic, or renal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, or any other clinically relevant abnormality, medical or psychiatric condition, which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study.

• History of alcohol or other substance abuse, according to the Diagnostic and Statistical Manual of Mental Disorders - Substance related disorders (DSM-IV) criteria.

• Clinically significant abnormalities in laboratory tests, including subjects with active liver disease or uncontrolled thyroid disease.

• Uncontrolled hypertension with systolic BP =160 and/or diastolic =95 mmHg. Subjects with controlled hypertension with systolic BP < 160 mmHg and diastolic <95 mmHg for at least 4 weeks are acceptable.

• Systolic BP <100 mmHg and/or diastolic <60 mmHg.

• Subjects with ECG criteria outside ranges specified in the protocol

• History of hypersensitivity to GSK239512 or its excipients.

• Treatment with cholinesterase inhibitors, (including Tacrine), memantine or selegiline within the previous month. No patients with AD who are already on these medications at the time of screening will be recruited, as it would be unethical to withdraw these medications for study participation. Only AD subjects who are not yet on these medications, or who have withdrawn from these medications for other reasons previously, may be enrolled into this study.

• Subjects who are currently taking or who have taken in the last month anti-psychotic drugs (typical or atypical dopaminergic antagonists or modulators) or mood stabilization drugs (including SSRI, DNRI, SNRI, MAO inhibitors, tricyclic antidepressants, lithium, valproate, carbamazepine).

• Subjects who are currently taking Pgp inhibitors or any CYP3A4 inhibitors.

• Subjects on chronic sedative medications (= 4 days per week for the past 4 weeks).

• Subject or caregiver is an immediate family member or employee of the participating Investigator, any of the participating site staff or GSK staff.

• Has received any other investigational treatment in the previous 3 months.

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Intervention

Drug:
• GSK239512
GSK239512 oral tablets once a day
• Placebo
Placebo tablets to match once a day

Locations

Country	Name	City	State
Australia	GSK Investigational Site	Heidelberg Heights	Victoria
Australia	GSK Investigational Site	Randwick	New South Wales
Czechia	GSK Investigational Site	Prague 10
Korea, Republic of	GSK Investigational Site	Seoul
Korea, Republic of	GSK Investigational Site	Seoul
United Kingdom	GSK Investigational Site	Cambridgeshire
United Kingdom	GSK Investigational Site	London
United Kingdom	GSK Investigational Site	Southall

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Australia,  Czechia,  Korea, Republic of,  United Kingdom, 

References & Publications (1)

Nathan PJ, Boardley R, Scott N, Berges A, Maruff P, Sivananthan T, Upton N, Lowy MT, Nestor PJ, Lai R. The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation. Curr Alzheimer Res. 2013 Mar;10(3):240-51. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability as measured by adverse events, vital signs clinical laboratory measurements and validated clinical assessment scales.		Days 8, 15, 22 and 29
Secondary	Pharmacodynamics measured by computerized cognitive tests and validated clinical rating scales. Also investigating the Pharmacokineticsat trough concentrations (Cmin) after GSK239512 repeat dosing on days 8, 15, 22 and 29 and 15.		days 8, 15, 22 and 29

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
•   Results for study H3B109689 can be found on the GSK Clinical Study Register.